Objective-Peroxisome proliferator-activated receptor γ, coactivator 1α (PGC-1α) is an important mediator of mitochondrial biogenesis and function. Because dysfunctional mitochondria might be involved in the pathogenesis of vascular disease, the current study was designed to investigate the effects of in vivo PGC-1α deficiency during chronic angiotensin II (ATII) treatment. Approach and Results-Although ATII infusion at subpressor doses (0.1 mg/kg per day for 7 days) did not cause vascular dysfunction in wild-type mice, it led to impaired endothelial-dependent and endothelial-independent relaxation in PGC-1α knockout mice. In parallel, oxidative stress was increased in aortic rings from ATII-treated PGC-1α knockout mice, whereas no change in nitric oxide production was observed. By using the mitochondrial-specific superoxide dye MitoSox and complex I inhibitor rotenone, we identified the mitochondrial respiratory chain as the major PGC-1α-dependent reactive oxygen species source in vivo, accompanied by increased vascular inflammation and cell senescence. In vivo treatment with the mitochondria-targeted antioxidant Mito-TEMPO partially corrected endothelial dysfunction and prevented vascular inflammation in ATII-treated PGC-1α mice, suggesting a causative role of mitochondrial reactive oxygen species in this setting.
I ncreased production of reactive oxygen species (ROS) plays a major role in the pathogenesis of endothelial dysfunction. Among putative ROS sources, the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, 1 mitochondrial respiratory chain, 2 xanthine oxidase, 3 and uncoupled endothelial nitric oxide (NO) synthase 4 have gathered particular interest in vascular biology. Recently, mitochondrial ROS production was shown to be involved in the development of hypertension because in vivo treatment with the mitochondria-targeted antioxidant Mito-TEMPO prevented increase in blood pressure in response to angiotensin II (ATII). 5 Therefore, the understanding of mechanisms that regulate mitochondrial ROS production may help to develop new strategies for the treatment of hypertension and vascular disease.
In this respect, the peroxisome proliferator coactivator 1α (PGC-1α) is a transcriptional coactivator of nuclear receptors involved in cellular energy metabolism, which regulates mitochondrial biogenesis and function. Recent studies have indicated that PGC-1α modulates intracellular ROS generation, for example, by increasing the expression of ROS-detoxifying enzymes in mitochondria. 6, 7 In addition, PGC-1α attenuates proliferation and migration of vascular smooth muscle cells 8 and reduces neointima formation after endothelial injury. 9 Because ATP production by mitochondria also requires sufficient nutrient and oxygen supply, it is not surprising that PGC-1α is also involved in vascular endothelial growth factor expression 10 and angiogenesis. 11 Besides oxidative stress, inflammation is increasingly appreciated as an important factor in the development of vascular disease. In this regard, PGC-1α overexpression prevented the tumor necrosis factor-α-induced activation of nuclear factor-κB, monocyte chemotactic protein-1, and vascular cell adhesion molecule 1 expression, 12 although its deletion did not slow down the atherosclerotic process in apolipoprotein E knockout mice. 13 In summary, the majority of available studies suggest that PGC-1α may protect against the development of vascular disease.
However, apart from atherosclerotic lesion formation, the role of PGC-1α for the regulation of vascular oxidative stress and function in vivo remains incompletely understood. Given the crucial role of mitochondrial ROS for the development of ATII-induced hypertension, 5 PGC-1α may interfere with this process through the modulation of mitochondrial function. Therefore, the current study was designed to investigate the consequences of PGC-1α deletion on vascular function, oxidative stress, inflammation, and cell senescence during chronic ATII treatment.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

PGC-1α Deletion Leads to Enhanced Vascular Dysfunction in Response to ATII
Although chronic ATII infusion at subpressor doses did not significantly impair endothelium-dependent vasodilation in wildtype animals, PGC-1α knockout mice showed a significant endothelial dysfunction after ATII treatment ( Figure 1A) , as well as an impairment of endothelial-independent relaxation ( Figure 1B ). Vascular relaxation critically depends on the balance of ROS and NO production by the vascular endothelium.
To determine whether the observed impairment in endothelial function in PGC-1α knockout mice was because of altered NO levels, we measured vascular endothelial NO synthase mRNA and protein expression, as well as vascular NO production, by electron paramagnetic resonance. However, these parameters were similar among all groups (Figures 1C and 1D; Figure III in the online-only Data Supplement), indicating that endothelial dysfunction in response to PGC-1α deletion is not attributable to decreased vascular NO production. In addition, no changes in body weight, glucose, or lipid metabolism were observed in response to PGC-1α deletion ( Figure I in the online-only Data Supplement).
As changes in hemodynamics may be another plausible explanation for the observed endothelial dysfunction in PGC-1α knockout mice, we next assessed blood pressure by using implanted indwelling telemetry catheters. We observed no significant change in blood pressure ( Figure IIB in the online-only Data Supplement). Because enhanced ATII signaling may activate ROS sources, such as the NADPH oxidase or the mitochondrial respiratory chain, we next examined vascular oxidative stress in response to PGC-1α deletion.
PGC-1α Deletion Enhances Systemic Oxidative Stress and Vascular ROS Production
As a surrogate of systemic oxidative stress, we observed a significant decline in serum antioxidant capacity in ATII-treated PGC-1α knockout mice (Figure 2A) . Similarly, aortic ROS production was significantly increased in ATII-treated PGC-1α knockout mice as measured by dihydroethidium staining ( Figure 2B and 2C) or lucigenin-enhanced chemiluminescence ( Figure 2D ). In accordance with the prominent role of PGC-1α for the regulation of mitochondrial mass and function, we identified the mitochondrial respiratory chain as the major PGC-1α-sensitive ROS source because vascular ROS production was completely inhibitable by preincubation of aortic rings with rotenone ( Figure 2C and 2D), an inhibitor of the mitochondrial electron transport chain that interferes with the transfer of electrons from complex I to ubiquinone, thereby preventing mitochondrial ROS formation. Accordingly, we observed the highest mitochondrial ROS levels in ATII-treated PGC-1α knockout mice (assessed by using the mitochondriatargeted superoxide dye MitoSox; Figure 3A and 3B), whereas in vitro treatment of aortic rings with rotenone normalized the superoxide signal. Interestingly, increased mitochondrial oxidative stress was also evident in CD31-positive endothelial cells because these cells exhibited an increased MitoSox fluorescence assessed by flow cytometry in a single-cell suspension of aortic tissue ( Figure 3C ). Because changes in mitochondrial ROS levels may be secondary to the modulation of the mitochondrial antioxidative defense governed by PGC-1α, 6 we next investigated the expression of heme oxygenase 1 (HO-1) and manganese superoxide dismutase as the primary ROS-scavenging enzyme in mitochondria. Although manganese superoxide dismutase levels were similar in all groups, we observed a significant induction of HO-1 expression in response to ATII in wild-type mice, which was completely blunted in PGC-1α knockout mice ( Figure 3D and 3E). Because HO-1 upregulation in response to ATII is likely because of an associated increase in oxidative stress, 14 the absence of this adaptive response in PGC-1α knockout mice may indicate an increased susceptibility toward oxidative damage in these animals. Because PGC-1α may also cause changes in mitochondrial number or function, it is important to note that mitochondrial mass and the expression of citrate synthase in vascular cells were not altered by PGC-1α deletion ( Figure IV in the online-only Data Supplement).
PGC-1α Deletion Augments Vascular Inflammation in Response to ATII
Because vascular inflammation is another important factor that contributes to vascular dysfunction during ATII-induced hypertension 15 and α1 AMP-activated protein kinase (α1AMPK) partially protects from ATII-induced inflammation, 16 we analyzed the influence of PGC-1α deletion on proinflammatory signaling pathways. In particular, we analyzed vascular expression of adhesion molecules (monocyte chemotactic protein-1, chemokine [C-C motif] ligand 5, vascular cell adhesion molecule 1), markers of macrophage infiltration (CD163, CD11b, CD68), and general inflammation (inducible NO synthase , cyclooxygenase-2, plasminogen activator inhibitor-1, tumor necrosis factor-α, interleukin 6). With the exemption of CD163, all these inflammation-related molecules were significantly upregulated in ATII-treated PGC-1α knockout compared with wild-type mice (Figure 4 and Figure V in the online-only Data Supplement), indicating that PGC-1α is an important modulator of the inflammatory milieu in the vasculature. Because high macrophage expression of CD163 defines an anti-inflammatory M2 macrophage subtype, this may explain why we observed no significant change in CD163 expression among all groups.
PGC-1α Deficiency Augments ATII-Induced Vascular Cell Senescence and Apoptosis
Mitochondrial oxidative stress and dysfunction are associated with cellular aging 2 and apoptosis, which may contribute to vascular dysfunction observed in PGC-1α knockout mice. In accordance with this notion, we found the highest aortic expression of the cell-cycle inhibitors cell-cycle checkpoint kinase 2 and p16 INK4 in ATII-treated PGC-1α knockout mice ( Figure 5A and 5B), indicating increased vascular cell senescence in these animals. One possible explanation for premature cell senescence constitutes the shortening of telomeres occurring during each cell cycle, a process that can be reversed by the enzyme telomerase. PGC-1α deletion led to a decreased expression of telomerase reverse transcriptase and telomere repeat-binding factor 2, 2 important components of the telomerase complex ( Figure 5C and 5D ). As enhanced cell senescence will ultimately result in cell death, we also investigated apoptosis in response to PGC-1α deletion. Enhanced vascular cell apoptosis assessed by terminal deoxynucleotidyl transferase dUTP nick end labeling staining was observed in mouse aortas after ATII infusion, whereas PGC-1α deletion led to considerable increase in the number of apoptotic cells ( Figure 5E ). We have previously shown that activation of the AMPK confers protection against ROS-induced c-Jun N-terminal kinase activation and endothelial cell death in a PGC-1α-dependent manner. 17 Along with these findings, we observed an increased activation of the c-Jun N-terminal kinase pathway in ATIItreated mice lacking PGC-1α ( Figure 5F ). Taken together, mitochondrial ROS production and dysfunction because of PGC-1α deletion enhance c-Jun N-terminal kinase signaling and eventually result in cell death-associated vascular dysfunction.
Mitochondrial ROS Play a Crucial Role for the Development of Vascular Dysfunction and Inflammation Because of PGC-1α Deletion
To study the role of mitochondrial ROS for the manifestation of vascular dysfunction because of PGC-1α deletion, mice received concomitant treatment with the mitochondria-targeted antioxidant Mito-TEMPO in vivo (200 mg/kg per day). The effectiveness of this approach was proven by MitoSox staining, which showed a significant reduction of the ROS signal after Mito-TEMPO cotreatment ( Figure 6A ). More importantly, Mito-TEMPO treatment partially restored endothelial dysfunction to a degree observed in ATII-treated wild-type mice ( Figure 6B ) and almost normalized the expression of inflammation-related molecules, including monocyte chemotactic protein-1, plasminogen activator inhibitor-1, and interleukin 6 ( Figure 6C-6E) . These findings suggest that PGC-1α deletion exerts its deleterious effects on the vasculature through an increase in mitochondrial ROS formation.
Discussion
In the current study, we provide evidence that PGC-1α is an important regulator of vascular oxidative stress in vivo. In accordance with the prominent role of PGC-1α for mitochondrial function, we identified the mitochondrial respiratory chain as the primary PGC-1α-dependent vascular ROS source. Among others, the NADPH oxidase, mitochondrial respiratory chain, and uncoupled endothelial NO synthase have all been implicated in the development of vascular disease, but their individual importance regarding vascular dysfunction is still a matter of debate. In this respect, the choice of the animal model of vascular disease may account for some of the observed differences. Although the NADPH oxidase is usually considered as one of the most important ROS sources in the vasculature, mitochondrial ROS formation seems particularly relevant to nitrate tolerance and 18 aging-associated 2 and diabetes mellitusassociated endothelial dysfunction. 19 The assessment of the origin of vascular oxidative stress is further complicated by a significant crosstalk between individual ROS sources in the vasculature, such as the NADPH oxidase and mitochondria. 20 In accordance with this notion, ATII was shown to increase mitochondrial ROS production in an NADPH oxidase-dependent manner 21 and vice versa. 5 These data may explain why the inhibition of only 1 ROS source may have profound functional implications as demonstrated for hypertension 5 or vascular function/inflammation in our study. Our results clearly demonstrate an aggravation of vascular dysfunction in PGC-1α knockout mice treated with ATII. In apolipoprotein E knockout mice with advanced atherosclerotic disease, deletion of PGC-1α did not slow down atherosclerotic lesion formation, although it reduced surrogates of vascular inflammation, such as plaque macrophage content and interleukin-18 plasma levels. The discrepancy of PGC-1α effects in these 2 models of vascular disease may relate to the different disease mechanisms. During overt atherosclerosis, proinflammatory mechanisms largely contribute to the vascular phenotype. PGC-1α knockout mice are characterized by decreased white adipose tissue, which may have prevented the acceleration of atherosclerosis by PGC-1α deletion in the mentioned study. 13 In contrast, in our model of ATII infusion, oxidative stress, apoptosis, and vascular cell senescence may constitute the dominant mechanisms of vascular disease, which were all modulated in a PGC-1α-dependent manner.
Our study identifies mitochondrial ROS production as a key element of how PGC-1α deletion exerts its deleterious effects on the vasculature because concomitant treatment with the mitochondria-targeted antioxidant Mito-TEMPO prevented the development of ATII-induced endothelial dysfunction. Interestingly, this strategy also led to decreased vascular inflammation, suggesting that the modulation of mitochondrial ROS by PGC-1α is an early event that may cause further vascular damage, for example, by induction of proinflammatory signaling pathways. Therefore, therapeutic interventions that target the AMPK-PGC-1α axis may be a future way to prevent mitochondrial ROS production and eventually the development of associated vascular disease.
Beyond increased mitochondrial ROS production, we identified vascular apoptosis and cell senescence as major contributors to vascular disease, which critically depend on the presence of PGC-1α. Although the discovery of endothelial progenitor cells has opened a new field of regenerative research, strategies to prevent endothelial cell death have gathered surprisingly little attention as a possible approach to prevent vascular disease. We have previously shown that activation of the AMPK limits ROS-induced cell death and preserves endothelial function in a PGC-1α-dependent manner. 17 Our current findings are in line with these observations because deletion of PGC-1α resulted in an exacerbation of vascular apoptosis and cell senescence. On the cellular level, telomeres are important regulators of the aging process. Each replicative cell cycle results in a shortening of telomere length, a process that can be reversed by telomerases. PGC-1α deletion resulted in a reduced aortic expression of components of the telomerase complex but an upregulation of cell-cycle checkpoint kinase 2 and p16 INK4 , indicative of increased vascular cell senescence. It was previously demonstrated that telomere dysfunction results in disruption of PGC-1α signaling, 22 whereas our study clearly shows that PGC-1α deletion also affects the integrity of the telomerase complex. Because there is a close relationship between mitochondrial function and cellular senescence, it is not surprising that PGC-1α, as a major regulator of mitochondrial mass and function, also affects vascular cell senescence. As PGC-1α critically regulates mitochondrial ROS formation, further studies will determine whether the observed effects on vascular aging might be a consequence of mitochondrial oxidative stress and disturbed mitochondrial function.
Another important finding of our study is the PGC-1αdependent upregulation of vascular HO-1. Because HO-1 is a cytoprotective protein whose expression is associated with therapeutic benefits in vascular disease, the complete loss of ATII-induced HO-1 upregulation in PGC-1α knockout mice likely contributes to the enhanced oxidative stress and vascular dysfunction in these animals. The expression of HO-1 is regulated by nuclear factor (erythroid-derived 2)-like 2, 23 which in turn is a known downstream target of PGC-1α, 24 suggesting that PGC-1α regulates HO-1 expression in a nuclear factor (erythroid-derived 2)-like 2-dependent manner. Furthermore, the AMPK-dependent upregulation of HO-1 in endothelial cells was shown to attenuate cell death. 25 It is tempting to speculate that HO-1 upregulation is an important factor of how PGC-1α exerts vascular protection, because (1) we observed increased vascular apoptosis but a blunted HO-1 upregulation in PGC-1α knockout mice and (2) we showed previously that the AMPK-dependent prevention of endothelial cell death requires PGC-1α. 17 Our results indicate that PGC-1α deletion during ATII treatment induces not only endothelial dysfunction but also impairs endothelial-independent relaxation. Therefore, it remains to be established whether PGC-1α expression in the endothelium or the vascular smooth muscle layer is crucial for the preservation of vascular function in this setting. Future studies with tissue-specific deletion of PGC-1α will help to address this important issue.
We conclude that the presence of PGC-1α in the vasculature is crucial to prevent mitochondrial ROS production and subsequent development of vascular dysfunction/inflammation in response to prooxidant stimuli, such as ATII. Mitochondrial reactive oxygen species have been implicated in the development of vascular disease, but novel strategies to modulate their production are limited. Here, we show that deletion of peroxisome proliferator coactivator 1α leads to an exacerbation of mitochondrial reactive oxygen species production in response to angiotensin II infusion in the vasculature, associated with impaired vascular dilation, increased vascular inflammation, and cellular senescence. Importantly, endothelial dysfunction and vascular inflammation were significantly improved by cotreatment with the mitochondria-targeted antioxidant Mito-TEMPO, indicating a crucial role of mitochondrial reactive oxygen species in this setting. Therefore, the preservation of peroxisome proliferator coactivator 1α activity may be an attractive target for future investigations to inhibit mitochondrial reactive oxygen species formation to prevent vascular disease.
Significance
